NTLA
Intellia Therapeutics, Inc
Latest price
As of Oct 26, 2026, 6:45 PM EDT · Market data by Massive
Market cap
$1.6B
Volume
2.1M
Previous close
$11.21
Day range
$11.09 – $11.44
Listed
May 6, 2016
Coverage
2 articles
Price performance
Recent trading
Newsroom
Latest NTLA coverage
Intellia Therapeutics Loses A Patient & $BILLIONS In Value — Can It Recover?
Intellia plunged after a patient died in its ATTR trial, prompting FDA holds on two Phase III studies and raising serious questions about safety, CRISPR risks, and the future of its pipeline.
Novel gene-editing therapy shows promise for patients with transthyretin amyloid cardiomyopathy
[ad_1] Research Highlights: In a clinical trial, a single intravenous infusion of NTLA-2001, a novel gene-editing therapy based on CRISPR/Cas9, significantly reduced abnormal levels of the protein transthyretin in patients with ATTR amyloid cardiomyopathy, a progressive and fatal cause of heart failure. Circulating TTR protein, which accumulates in the